T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.6B |
| 2 |
BNY
Bank of New York Mellon
BNY
|
+$1.1B |
| 3 |
Elevance Health
ELV
|
+$903M |
| 4 |
DD
Du Pont De Nemours E I
DD
|
+$873M |
| 5 |
Medtronic
MDT
|
+$868M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.89B |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.06B |
| 3 |
CFN
CAREFUSION CORPORATION
CFN
|
+$946M |
| 4 |
Aptiv
APTV
|
+$886M |
| 5 |
KSU
Kansas City Southern
KSU
|
+$662M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.05% |
| 2 | Consumer Discretionary | 13.82% |
| 3 | Financials | 13.14% |
| 4 | Industrials | 11.9% |
| 5 | Technology | 9.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Teva Pharmaceuticals
TEVA
$42.8B
| $462M | 0.1% |
7,411,560
+1,326,854
| +22% | +$77.1M |
|
|
GGP
252
DELISTED
GGP Inc.
GGP
| $462M | 0.1% |
15,621,879
-165,478
| -1% | -$4.94M |
|
|
K
253
DELISTED
Kellanova
K
| $462M | 0.1% |
7,452,701
-368,247
| -5% | -$22.5M |
|
|
HCC
254
DELISTED
HCC INSURANCES HOLDINGS INC
HCC
| $461M | 0.1% |
8,134,030
+76,880
| +1% | +$4.26M |
|
255
Clorox
CLX
$12.8B
| $458M | 0.09% |
4,147,380
-306,350
| -7% | -$33.3M |
|
256
Allegiant Air
ALGT
$2.31B
| $457M | 0.09% |
2,377,734
-136,700
| -5% | -$24.5M |
|
257
Nucor
NUE
$61.9B
| $456M | 0.09% |
9,590,004
-340,210
| -3% | -$15.9M |
|
|
CLGX
258
DELISTED
Corelogic, Inc.
CLGX
| $449M | 0.09% |
12,717,496
+933,585
| +8% | +$31.5M |
|
|
WWAV
259
DELISTED
The WhiteWave Foods Company
WWAV
| $448M | 0.09% |
10,112,751
-1,277,859
| -11% | -$48.8M |
|
260
Zillow
ZG
$7.53B
| $446M | 0.09% |
13,353,435
+3,696,915
| +38% | +$131M |
|
261
ManpowerGroup
MAN
$2.61B
| $446M | 0.09% |
5,177,540
-827,593
| -14% | -$63M |
|
262
News Corp Class A
NWSA
$15.5B
| $445M | 0.09% |
27,800,806
+481,383
| +2% | +$7.79M |
|
|
SBNY
263
DELISTED
Signature Bank
SBNY
| $437M | 0.09% |
3,368,873
+76,502
| +2% | +$9.5M |
|
264
Quest Diagnostics
DGX
$26.2B
| $434M | 0.09% |
5,652,416
-1,876,110
| -25% | -$134M |
|
265
Southwest Airlines
LUV
$22B
| $426M | 0.09% |
9,625,833
-1,063,590
| -10% | -$46.5M |
|
266
Public Storage
PSA
$60.4B
| $419M | 0.09% |
2,124,912
+43,604
| +2% | +$8.64M |
|
267
Viatris
VTRS
$18.5B
| $416M | 0.09% |
7,003,207
+2,521,795
| +56% | +$144M |
|
268
Cardinal Health
CAH
$54.5B
| $412M | 0.09% |
4,562,289
-373,859
| -8% | -$32.2M |
|
|
WCG
269
DELISTED
Wellcare Health Plans, Inc.
WCG
| $411M | 0.09% |
4,497,065
+741,476
| +20% | +$61.9M |
|
270
Xerox
XRX
$412M
| $411M | 0.08% |
12,124,874
-1,318,682
| -10% | -$46.5M |
|
271
Macy's
M
$6.26B
| $409M | 0.08% |
6,303,341
-691,821
| -10% | -$44.5M |
|
272
Illumina
ILMN
$29.1B
| $408M | 0.08% |
2,257,415
+26,322
| +1% | +$4.96M |
|
273
Intel
INTC
$509B
| $407M | 0.08% |
13,021,373
+4,100,615
| +46% | +$138M |
|
274
Dollar General
DG
$26.4B
| $406M | 0.08% |
5,390,992
+76,732
| +1% | +$5.43M |
|
|
CVC
275
DELISTED
CABLEVISION SYS CP NY GRP CL-A
CVC
| $406M | 0.08% |
22,186,837
+41,002
| +0.2% | +$786K |
|
Similar funds
T. Rowe Price Associates's Q1 2015 Portfolio in Review
As of Q1 2015, T. Rowe Price Associates held 2,630 positions worth $484B, up 2.8% from $471B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q1 2015 filing shows 93 new, 1,078 increased, 887 reduced and 93 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M. The largest sale was Allergan Inc, an estimated $3.89B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M.
- T. Rowe Price Associates added most to Allergan plc in Q1 2015, an estimated $2.6B increase.
- T. Rowe Price Associates's biggest Q1 2015 reduction was Aptiv, cutting an estimated $886M.
- T. Rowe Price Associates fully exited Allergan Inc in Q1 2015, selling an estimated $3.89B.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $484B portfolio in Q1 2015.
- T. Rowe Price Associates opened 93 new positions and closed 93 in Q1 2015.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $484B.
Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.